# Parasitic Clearance and Recurrence Rates Among Patients With Vivax Malaria

> **NCT01784315** · — · UNKNOWN · sponsor: **Ministry of Health, Bhutan** · enrollment: 50 (estimated)

## Conditions studied

- Parasitemia

## Interventions

- **DRUG:** Artemisinin combination therapies (ACT)will be used for Chloroquine resistant P.vivax
- **DRUG:** Chloroquine and Primaquine

## Key facts

- **NCT ID:** NCT01784315
- **Lead sponsor:** Ministry of Health, Bhutan
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-03
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2013-11-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01784315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01784315, "Parasitic Clearance and Recurrence Rates Among Patients With Vivax Malaria". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01784315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*